SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-027217
Filing Date
2023-08-03
Accepted
2023-08-03 16:11:38
Documents
62
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ngm-20230630.htm   iXBRL 10-Q 1276503
2 EX-31.1 ngm-20230630x10qex311.htm EX-31.1 11092
3 EX-31.2 ngm-20230630x10qex312.htm EX-31.2 10850
4 EX-32.1 ngm-20230630x10qex321.htm EX-32.1 8032
  Complete submission text file 0001628280-23-027217.txt   5959085

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20230630.xsd EX-101.SCH 36119
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ngm-20230630_cal.xml EX-101.CAL 47886
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ngm-20230630_def.xml EX-101.DEF 175580
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20230630_lab.xml EX-101.LAB 596891
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20230630_pre.xml EX-101.PRE 355170
56 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20230630_htm.xml XML 724963
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38853 | Film No.: 231140087
SIC: 2834 Pharmaceutical Preparations